Abeona Therapeutics (NASDAQ:ABEO) Upgraded at StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

Several other research analysts have also weighed in on the company. Oppenheimer assumed coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a report on Monday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Abeona Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $17.50.

Abeona Therapeutics Trading Down 0.6 %

ABEO traded down $0.03 during midday trading on Monday, hitting $5.12. The company’s stock had a trading volume of 455,643 shares, compared to its average volume of 402,180. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $8.45. The firm has a 50-day moving average price of $5.43 and a two-hundred day moving average price of $5.83. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The firm has a market cap of $222.57 million, a P/E ratio of -1.90 and a beta of 1.79.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19. On average, research analysts anticipate that Abeona Therapeutics will post -1.16 earnings per share for the current year.

Institutional Trading of Abeona Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP acquired a new position in shares of Abeona Therapeutics during the fourth quarter worth about $520,000. Western Standard LLC lifted its position in Abeona Therapeutics by 22.8% during the 4th quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock worth $11,610,000 after acquiring an additional 386,321 shares in the last quarter. Squarepoint Ops LLC purchased a new position in Abeona Therapeutics in the 4th quarter worth approximately $67,000. Twinbeech Capital LP acquired a new stake in Abeona Therapeutics in the fourth quarter valued at approximately $58,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Abeona Therapeutics during the fourth quarter valued at approximately $362,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.